E-103 Short-term in-hospital outcomes of thrombolysis for acute ischemic stroke patients with non-primary brain tumors and congestive heart failure

Raymond Kai‐Yu Tong, Trenton D. Colburn, Patrick M. Brauer2019 · DOI

Abstract

Intravenous thrombolysis is a critical intervention for acute ischemic stroke (AIS), yet its application is often limited by patient comorbidities. While previous research has explored the safety of thrombolysis in patients with brain tumors, the impact of congestive heart failure (CHF) on short-term outcomes remains a significant clinical concern. This study utilizes data from the Nationwide Inpatient Sample (NIS) to evaluate how CHF influences mortality, length of stay, and hospital charges for AIS patients receiving thrombolytic therapy.

Introduction

Intravenous thrombolysis remains the gold standard pharmacological treatment for acute ischemic stroke (AIS). Despite its efficacy, many patients are excluded from treatment due to various contraindications. While recent studies have suggested that certain conditions, such as benign brain tumors, may not significantly worsen outcomes, other systemic comorbidities like congestive heart failure (CHF) present a more complex clinical picture. This study aimed to investigate the short-term in-hospital outcomes of thrombolytic treatment in AIS patients without primary brain tumors, specifically comparing those with and without a diagnosis of CHF.

Methods

This retrospective cohort study analyzed data from the Nationwide Inpatient Sample (NIS) spanning from 2012 through the third quarter of 2015. The NIS provides a robust, stratified sample representing approximately 20% of all hospital discharges across the United States.

The study population included adult patients (aged 18 and older) who were hospitalized for AIS and received intravenous thrombolysis. Researchers used ICD-9 codes to identify patients with a secondary diagnosis of CHF. To ensure a focused analysis, patients with primary brain tumors (both benign and malignant) were excluded, as were those with missing demographic or mortality data. The primary outcomes measured were in-hospital mortality rate, length of stay (LOS), total hospital charges, and age at admission.

Results

The final cohort consisted of 24,692 AIS patients treated with thrombolysis. Within this group, 4,130 patients (approximately 16.7%) were identified as having comorbid CHF.

The analysis revealed significant differences across all measured metrics:

  • Mortality: The presence of CHF was associated with a statistically significant increase in the mortality rate (p < 0.0001).
  • Length of Stay (LOS): Patients with CHF experienced significantly longer hospitalizations, averaging 7.63 days compared to 6.08 days for those without CHF (p < 0.0001).
  • Hospital Charges: Financial outcomes mirrored the clinical data, with average total charges significantly higher for the CHF group ($96,978.03) compared to the non-CHF group ($83,905.14) (p < 0.0001).
  • Age: Patients in the CHF cohort were significantly older, with a mean age of 70.68 years versus 66.32 years in the non-CHF cohort (p < 0.0001).

Discussion

The findings underscore the systemic nature of vascular health, reinforcing that a stroke is not merely a neurological event but a systemic one. The presence of CHF significantly complicates the clinical course for AIS patients receiving thrombolysis. The increased length of stay and higher hospital charges suggest that these patients require more intensive resource utilization, likely due to the management of cardiac complications, specialized monitoring, or a higher degree of physiological frailty.

The age difference between the two groups—with CHF patients being nearly four years older on average—indicates that age-related frailty may compound the risks associated with heart failure. Furthermore, the economic burden of nearly $13,000 in additional charges per stay highlights the need for optimized care pathways for this specific subpopulation.

A key takeaway for clinicians is the importance of the "heart-brain connection." The study suggests that the management of a patient's cardiac status before and during the administration of thrombolysis may be a critical factor in improving short-term outcomes. Prioritizing pre-treatment stabilization could potentially mitigate some of the risks identified in this cohort.

Conclusion

Congestive heart failure is a significant predictor of poorer short-term outcomes in AIS patients treated with intravenous thrombolysis. These patients face higher mortality, longer hospital stays, and increased medical costs. These results suggest that clinicians should place a heightened focus on stabilizing and managing CHF in the context of acute stroke care. Future research is needed to determine if specific thrombolytic agents (such as Tenecteplase vs. Alteplase) or more tailored cardiac management protocols can improve the prognosis for this vulnerable patient population.

Summary updated

Abstract

<h3>Background</h3> Intravenous thrombolysis remains an underutilized treatment for acute ischemic stroke (AIS) due to several relative and absolute contraindications. Previous studies have found similar outcomes after thrombolysis between AIS patients with benign brain tumors and AIS patients without. This study aims to investigate short-term outcomes of thrombolytic treatment for the greater majority of AIS patients who have no history of primary brain tumors, particularly those with congestive heart failure (CHF). <h3>Methods</h3> This retrospective cohort study utilized data from the 2012–2015Q3 Nationwide Inpatient Sample (NIS). ICD-9 codes identified adult patients (ages 18+) who suffered acute ischemic stroke and received intravenous thrombolysis, and then further isolated patients diagnosed with CHF. Data for patients who were missing important clinical identifiers (age, gender, race, mortality), did not receive IV thrombolysis, and had primary brain tumors (benign or malignant) were excluded. Data analyses assessed hospital mortality rate, length of stay (LOS), inpatient charges, and average age of admission. <h3>Results</h3> Of the 24,692 encounters with AIS patients treated with thrombolysis and had no history of primary brain tumors, 4130 were diagnosed with CHF. Mean mortality rate was significantly increased (11.3% CHF vs. 11.8% no CHF, p&lt;0.0001). Mean LOS was significantly longer (7.63 days CHF vs. 6.08 days no CHF, p&lt;0.0001). Average total charges were significantly increased ($96,978.03 CHF vs. $83,905.14 no CHF, p&lt;0.0001). Average age at admission was significantly older (70.68 years CHF vs. 66.32 years no CHF, p&lt;0.0001). <h3>Conclusion</h3> This study aims to inform physicians to better manage AIS patients receiving IV thrombolysis with CHF and no history of primary brain tumors. These patients experience higher mortality rate, longer LOS, increased total hospital charges, and older age at admission than those without CHF. These findings suggest that placing clinical focus on the coexisting condition of CHF before administering IV thrombolysis for AIS may be critical for improving short-term in-hospital outcomes. Future research should aim to investigate different thrombolytic agents to determine the most optimal choice for patients with congestive heart failure. <h3>Disclosures</h3> <b>K. Tong:</b> None. <b>T. Colburn:</b> None. <b>P. Brauer:</b> None.
BibTeX
@misc{tong2019e,
  author = {Raymond Kai‐Yu Tong and Trenton D. Colburn and Patrick M. Brauer},
  title = {{E-103 Short-term in-hospital outcomes of thrombolysis for acute ischemic stroke patients with non-primary brain tumors and congestive heart failure}},
  year = {2019},
  doi = {10.1136/neurintsurg-2019-snis.178},
}
Figure